AUS
NZ
UK
CA
USA
IND
Healthcare
Botanix biotech pathway within All Ordinaries market structure
January 27, 2026 01:00 PM AEDT| By SamBiotechnology sector content covering Botanix commercial activity, Sofdra positioning, revenue mechanics, and participation within the All Ordinaries index.
4DMedical within All Ordinaries healthcare technology landscape
January 27, 2026 12:31 PM AEDT| By Sam4DMedical operates in the Australian healthcare technology sector, focusing on imaging-based respiratory assessment and lying on the All Ordinaries index.
Telix Pharmaceuticals across ASX 200 and All Ordinaries healthcare space
January 27, 2026 11:07 AM AEDT| By SamTelix Pharmaceuticals operates within the Australian pharmaceuticals sector, reflecting regulated healthcare activities and representation across major ASX indices.
Genetic Signatures (ASX:GSS) Shares Move With All Ordinaries Index
January 23, 2026 05:24 PM AEDT| By SamAn objective review of Genetic Signatures Limited highlighting biotechnology operations, sector placement, and its role within the All Ordinaries equity universe.
All Ordinaries healthcare focus shaped by Immutep clinical developments
January 23, 2026 03:18 PM AEDT| By SamImmutep coverage focusing on biotechnology research activity, regulatory environment, and inclusion within the All Ordinaries healthcare segment.
Anteris Advances Heart Valve Innovation With Landmark Capital Support
January 23, 2026 02:08 PM AEDT| By SamAnteris strengthens its growth path through major funding, advancing clinical trials and manufacturing to support next-generation heart valve innovation on a global scale.
ASX 200 Spotlight: CSL Outlook After Strategic Shift
January 23, 2026 01:52 PM AEDT| By SamCSL’s evolving outlook highlights a shift toward stability, disciplined execution, and long-term value within the Australian healthcare sector and the broader equity market.
Radiopharm’s Insider Activity Signals Market Attention on ASX
January 23, 2026 12:19 PM AEDT| By SamRadiopharm Theranostics is drawing attention as insider activity highlights confidence amid shifting healthcare market dynamics within the Australian equities landscape.
All Ordinaries focus as Anteris advances medical technology presence
January 23, 2026 12:10 PM AEDT| By SamAnteris medical technology coverage focusing on sector operations, capital activity context, and inclusion within the All Ordinaries index.
Mesoblast (ASX:MSB) Advances Cell Therapy for Back Pain with FDA Insights
January 22, 2026 05:46 PM AEDT| By SamMesoblast (ASX:MSB) advances chronic back pain cell therapy with FDA insights, highlighting long-term pain relief, opioid reduction, and growth prospects, offering a key update for ASX investors and biotech followers.
CSL Share Update: Key Insights Ahead of February Results
January 22, 2026 05:43 PM AEDT| By SamCSL Ltd (CSL.AX) gains on ASX rally as investors await February half-year results, focusing on plasma collection, vaccine demand, and sector trends.
Osteopore’s Hong Kong Entry Signals New Chapter in Asia Growth
January 22, 2026 04:03 PM AEDT| By SamExplore how Osteopore’s Hong Kong expansion strengthens its Asia footprint, supports advanced orthopaedic care, and connects with broader trends shaping the regional medical device and ASX stock market landscape.
ASX 200 Watch: 4DMedical Strengthens Market Position
January 22, 2026 02:53 PM AEDT| By Sam4DMedical’s latest market update highlights steady capital management, reinforcing its role within Australia’s evolving healthcare and technology landscape while supporting broader market stability.
ASX 200 Spotlight: Sonic Healthcare’s Valuation Story Unfolds
January 22, 2026 12:20 PM AEDT| By SamSonic Healthcare remains a key ASX 200 healthcare name, with valuation discussions now shaped by earnings quality, cash flow strength, and its long-term role in the sector.
Proteomics International Activity Within ASX 200 Today Healthcare Framework
January 21, 2026 04:52 PM AEDT| By SamProteomics International has released an ASX update on the quotation of newly issued shares, reflecting standard disclosure practices within Australia’s healthcare and biotechnology sector.
Healthcare Innovation Spotlight as LTR Pharma Engages ASX 300 Framework
January 21, 2026 04:25 PM AEDT| By SamLTR Pharma released a healthcare sector update outlining an exchange-related step tied to issued capital, aligning with standard disclosure practices across Australian market indices.
Adheris Health (ASX:AHE) Shares Track All Ordinaries Index
January 21, 2026 04:21 PM AEDT| By SamA factual review of Adheris Health Limited covering sector placement, digital healthcare services, and broader market context referenced through the All Ordinaries.
Mesoblast Advances Regenerative Medicine Operations Within ASX 200 Market Structure
January 21, 2026 04:17 PM AEDT| By SamMesoblast operates within the biotechnology sector, advancing regenerative cellular therapies while maintaining representation within the ASX 200 and ASX 300 indices.
Telix Pharmaceuticals Operates Within Biotechnology Sector Under ASX 200 Market Framework
January 21, 2026 02:51 PM AEDT| By SamTelix Pharmaceuticals operates within the biotechnology sector, delivering radiopharmaceutical innovation while maintaining inclusion within the ASX 200, ASX 300, and All Ordinaries indices.
ASX 200 Spotlight: 4DMedical Expands Market Presence With New Share Quotation
January 21, 2026 11:40 AM AEDT| By Sam4DMedical strengthens its ASX presence through a new share quotation, reinforcing momentum in Australia’s healthcare technology sector and reflecting broader market evolution.
Advertise your brand on Kalkine Media